- Home
- CLRB vs BCDA Comparison
CLRB vs BCDA Comparison
Compare CLRB & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- BCDA
- Stock Information
- Founded
- CLRB 2002
- BCDA N/A
- Country
- CLRB United States
- BCDA United States
- Employees
- CLRB N/A
- BCDA N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- BCDA Health Care
- Exchange
- CLRB Nasdaq
- BCDA Nasdaq
- Market Cap
- CLRB 12.5M
- BCDA 11.0M
- IPO Year
- CLRB N/A
- BCDA N/A
- Fundamental
- Price
- CLRB $7.90
- BCDA $2.15
- Analyst Decision
- CLRB Hold
- BCDA Strong Buy
- Analyst Count
- CLRB 2
- BCDA 1
- Target Price
- CLRB N/A
- BCDA $25.00
- AVG Volume (30 Days)
- CLRB 1.3M
- BCDA 52.3K
- Earning Date
- CLRB 08-12-2025
- BCDA 08-12-2025
- Dividend Yield
- CLRB N/A
- BCDA N/A
- EPS Growth
- CLRB N/A
- BCDA N/A
- EPS
- CLRB N/A
- BCDA N/A
- Revenue
- CLRB N/A
- BCDA $3,000.00
- Revenue This Year
- CLRB N/A
- BCDA N/A
- Revenue Next Year
- CLRB N/A
- BCDA N/A
- P/E Ratio
- CLRB N/A
- BCDA N/A
- Revenue Growth
- CLRB N/A
- BCDA N/A
- 52 Week Low
- CLRB $6.50
- BCDA $1.63
- 52 Week High
- CLRB $94.50
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- CLRB 40.04
- BCDA 51.13
- Support Level
- CLRB $9.60
- BCDA $1.98
- Resistance Level
- CLRB $10.19
- BCDA $2.45
- Average True Range (ATR)
- CLRB 1.57
- BCDA 0.17
- MACD
- CLRB -0.50
- BCDA 0.01
- Stochastic Oscillator
- CLRB 11.58
- BCDA 53.19
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).